{"id":"highly-active-antiretroviral-therapy-haart","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"30%","severity":"Moderate"},{"effect":"Headache","drugRate":"25%","severity":"Mild"},{"effect":"Diarrhea","drugRate":"20%","severity":"Moderate"},{"effect":"Fatigue","drugRate":"15%","severity":"Mild"},{"effect":"Rash","drugRate":"10%","severity":"Mild"}],"contraindications":[],"specialPopulations":{}},"trials":[],"_chembl":{"chemblId":"CHEMBL4802227","moleculeType":"Small molecule","molecularWeight":"274.11"},"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Highly Active Antiretroviral Therapy (HAART) is a combination of antiretroviral drugs used to treat HIV infection. HAART works by inhibiting the replication of the virus in the body, thereby reducing the viral load and improving immune function. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), HAART has been pivotal in transforming HIV from a fatal disease to a manageable chronic condition. The therapy typically consists of at least three different drugs from two or more classes, which helps prevent the development of drug-resistant strains of the virus. Despite its effectiveness, HAART can have significant side effects, and careful monitoring is required to manage these issues.","ecosystem":[],"mechanism":{"target":"HIV enzymes and processes","novelty":"HAART represents a significant advancement in HIV treatment by combining multiple drugs to achieve a synergistic effect and reduce the risk of resistance.","modality":"Combination therapy","drugClass":"Antiretroviral","explanation":"HAART uses a combination of drugs that target different stages of the HIV life cycle, such as reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors, to effectively suppress viral replication.","oneSentence":"HAART combines multiple antiretroviral drugs to inhibit different stages of the HIV life cycle, thereby reducing viral replication and improving immune function.","technicalDetail":"The drugs in HAART work by blocking key enzymes and processes that HIV uses to replicate, including reverse transcriptase, protease, and integrase, which are essential for the virus to integrate into the host cell's DNA and produce new viral particles."},"_scrapedAt":"2026-03-28T00:22:39.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":null,"launchDate":null,"annualCostUS":null,"currentRevenue":null,"patientPopulation":"HIV-positive individuals","peakSalesEstimate":null},"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":["HIV infection"],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07357584","phase":"PHASE4","title":"Efficacy and Safety of Doravirine in the Rapid Initiation","status":"NOT_YET_RECRUITING","sponsor":"Fundación Huésped","startDate":"2026-07-13","conditions":"HIV-1-infection","enrollment":100},{"nctId":"NCT04087239","phase":"","title":"The University of Zimbabwe College of Health Science (UZ-CHS) BIRTH COHORT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Zimbabwe","startDate":"2016-01-26","conditions":"HIV Infections, Immune Activation, Comorbidities","enrollment":1200},{"nctId":"NCT05898841","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2023-05-26","conditions":"HIV Infections, Fatty Liver Disease","enrollment":63},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT00167674","phase":"PHASE2","title":"ARVs to Prevent Breastmilk HIV:Viral and Immune Responses","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-11-03","conditions":"HIV Infections","enrollment":58},{"nctId":"NCT01634477","phase":"","title":"Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study","status":"COMPLETED","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2010-01","conditions":"HIV Infection, Healthy","enrollment":816},{"nctId":"NCT01614405","phase":"NA","title":"Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2012-06","conditions":"Primary Biliary Cirrhosis","enrollment":13},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT00867048","phase":"PHASE4","title":"Strategic Timing of Antiretroviral Treatment","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2009-04-15","conditions":"HIV Infection","enrollment":4688},{"nctId":"NCT00106171","phase":"PHASE4","title":"Anti-HIV Medications for People Recently Infected With HIV","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2005-05","conditions":"HIV Infections","enrollment":113},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":"HIV Infection","enrollment":1653},{"nctId":"NCT00775606","phase":"PHASE4","title":"Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2008-10","conditions":"Acquired Immune Deficiency Syndrome","enrollment":15},{"nctId":"NCT00289952","phase":"PHASE2","title":"Valproic Acid and Its Effects on HIV Latent Reservoirs","status":"COMPLETED","sponsor":"Jean-Pierre Routy","startDate":"2006-06","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT01013415","phase":"PHASE1","title":"CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2001-09","conditions":"HIV-1 Infections","enrollment":17},{"nctId":"NCT00145795","phase":"PHASE4","title":"A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2004-04","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00000891","phase":"PHASE2","title":"Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT00001075","phase":"NA","title":"The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00270205","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-01","conditions":"HIV Infections","enrollment":28},{"nctId":"NCT00614640","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00107549","phase":"PHASE1","title":"Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT00076518","phase":"PHASE2","title":"The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hypertriglyceridemia","enrollment":100},{"nctId":"NCT00013871","phase":"NA","title":"Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Measles","enrollment":300},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":""},{"nctId":"NCT00257127","phase":"NA","title":"Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02","conditions":"HIV Infections","enrollment":101},{"nctId":"NCT00006066","phase":"PHASE1","title":"Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT00050921","phase":"NA","title":"Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT00000943","phase":"NA","title":"A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT00000899","phase":"PHASE1","title":"A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":10},{"nctId":"NCT00000895","phase":"NA","title":"A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Mycobacterium Avium-intracellulare Infection, HIV Infections","enrollment":85},{"nctId":"NCT00872872","phase":"NA","title":"Nevirapine Clearance After Short-term Highly Active Antiretroviral Therapy (HAART) for Prevention of Mother to Child Transmission of HIV (PMTCT)","status":"COMPLETED","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2008-05","conditions":"NVP Plasma Level, NVP Related Mutation, 3TC Related Mutation","enrollment":30},{"nctId":"NCT04138199","phase":"","title":"A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation","status":"TERMINATED","sponsor":"AbbVie","startDate":"2019-11-01","conditions":"HIV-1 Infection","enrollment":239},{"nctId":"NCT00511056","phase":"","title":"Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2007-09","conditions":"HIV Infections","enrollment":700},{"nctId":"NCT01225406","phase":"","title":"Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2010-08","conditions":"This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy","enrollment":56},{"nctId":"NCT01428596","phase":"PHASE1","title":"Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects","status":"UNKNOWN","sponsor":"GeneCure Biotechnologies","startDate":"2010-09","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT00267865","phase":"PHASE2","title":"Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-09-14","conditions":"AIDS-Related-Primary Central Nervous System Lymphoma","enrollment":12},{"nctId":"NCT00339456","phase":"PHASE3","title":"Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in Uganda","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08-21","conditions":"HIV","enrollment":155},{"nctId":"NCT00001899","phase":"","title":"Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1998-12-16","conditions":"HIV Infection","enrollment":38},{"nctId":"NCT00518154","phase":"PHASE2","title":"Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2007-09","conditions":"HIV Infections","enrollment":7},{"nctId":"NCT00043641","phase":"","title":"HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-07-26","conditions":"HIV Infections","enrollment":73},{"nctId":"NCT01229761","phase":"PHASE2","title":"Study to Improve Survival Among HIV-Exposed Infants in Botswana","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2011-05","conditions":"HIV Infections, Neutropenia, Anemia","enrollment":3724},{"nctId":"NCT01488942","phase":"NA","title":"Use of Incentives to Retain Drug Users in HIV Therapy","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2012-12","conditions":"HIV Infection","enrollment":139},{"nctId":"NCT02581202","phase":"","title":"The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-21","conditions":"HIV-1 Infection","enrollment":216},{"nctId":"NCT02563509","phase":"PHASE1","title":"Reconstitution of HIV-specific Immunity Against HIV","status":"COMPLETED","sponsor":"Guangzhou 8th People's Hospital","startDate":"2016-01","conditions":"HIV","enrollment":30},{"nctId":"NCT02054286","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).","status":"COMPLETED","sponsor":"Theravectys S.A.","startDate":"2012-12","conditions":"HIV Infection","enrollment":38},{"nctId":"NCT01227044","phase":"PHASE2, PHASE3","title":"Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-04","conditions":"Reduction in Heavy Drinking in Patients With HIV","enrollment":51},{"nctId":"NCT01752569","phase":"PHASE1, PHASE2","title":"A Study of Selumetinib in Patients With Kaposi's Sarcoma","status":"TERMINATED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2012-06-15","conditions":"AIDS-related Kaposi's Sarcoma","enrollment":19},{"nctId":"NCT03838497","phase":"PHASE4","title":"Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Among HIV-infected Adults","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2015-04-02","conditions":"Streptococcal Pneumonia, HIV/AIDS","enrollment":70},{"nctId":"NCT00945282","phase":"PHASE2","title":"Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-10-20","conditions":"Infection, Human Immunodeficiency Virus","enrollment":8},{"nctId":"NCT01403051","phase":"PHASE2","title":"High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-09","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01262976","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-17","conditions":"Tuberculosis","enrollment":240},{"nctId":"NCT01697540","phase":"","title":"Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2012-09","conditions":"HIV","enrollment":100},{"nctId":"NCT00428116","phase":"NA","title":"Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":140},{"nctId":"NCT00531986","phase":"PHASE4","title":"HIV - Monotherapy in Switzerland (MOST-ch)","status":"TERMINATED","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2007-01","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT02063880","phase":"NA","title":"Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2013-03","conditions":"Human Immunodeficiency Virus, Immune Reconstitution Inflammatory Syndrome","enrollment":183},{"nctId":"NCT00433030","phase":"","title":"Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2007-01","conditions":"HIV Infections","enrollment":2816},{"nctId":"NCT00991302","phase":"NA","title":"Durability of Adherence in Self-Management of HIV","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2010-01","conditions":"HIV Infections","enrollment":172},{"nctId":"NCT00528957","phase":"PHASE3","title":"Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-12-28","conditions":"HIV Infections","enrollment":97},{"nctId":"NCT02794545","phase":"NA","title":"Functional Cure Study of HIV-infected Patients","status":"COMPLETED","sponsor":"Kaohsiung Medical University Chung-Ho Memorial Hospital","startDate":"2014-10","conditions":"HIV","enrollment":20},{"nctId":"NCT01924286","phase":"PHASE3","title":"Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2013-08-30","conditions":"Immune Reconstitution Inflammatory Syndrome, HIV, Tuberculosis","enrollment":240},{"nctId":"NCT00705926","phase":"PHASE1","title":"Effectiveness of Antiretroviral Therapy During Acute HIV Infection","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-10","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT02527096","phase":"PHASE2","title":"A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-09-17","conditions":"HIV-1 Infection","enrollment":110},{"nctId":"NCT01009749","phase":"NA","title":"Motivational Enhancement System for Adherence","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-08","conditions":"HIV","enrollment":76},{"nctId":"NCT00009256","phase":"","title":"Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2000-04-13","conditions":"HIV Infection","enrollment":65},{"nctId":"NCT00710593","phase":"PHASE2","title":"Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-02","conditions":"HIV Infection","enrollment":99},{"nctId":"NCT00140244","phase":"PHASE2","title":"Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-12","conditions":"HAART-induced Lipodystrophy and Metabolic Syndrome","enrollment":7},{"nctId":"NCT00491556","phase":"NA","title":"Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2007-10","conditions":"HIV Infections","enrollment":102},{"nctId":"NCT00987948","phase":"PHASE2","title":"Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels","status":"COMPLETED","sponsor":"University of Hawaii","startDate":"2010-01","conditions":"HIV Infections","enrollment":15},{"nctId":"NCT01845298","phase":"NA","title":"Immune Activation and Drug Absorption in HIV-Infected Patients","status":"COMPLETED","sponsor":"Drexel University","startDate":"2014-06","conditions":"HIV Infection","enrollment":7},{"nctId":"NCT00686049","phase":"","title":"HIV Treatment-Readiness Measure (HTRM) Validation","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2008-05","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00683579","phase":"","title":"Neurocognitive Assessment in Youth Initiating HAART","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2007-12","conditions":"HIV Infections","enrollment":220},{"nctId":"NCT01539005","phase":"","title":"Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2009-11","conditions":"Tuberculosis","enrollment":402},{"nctId":"NCT02614950","phase":"NA","title":"Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection","status":"COMPLETED","sponsor":"SEARCH Research Foundation","startDate":"2016-02","conditions":"Acute HIV Infection, Antiretroviral Treatment Interruption","enrollment":8},{"nctId":"NCT00056797","phase":"PHASE2","title":"Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-03","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT00232908","phase":"PHASE4","title":"QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"HIV Infections","enrollment":361},{"nctId":"NCT01500616","phase":"PHASE3","title":"Telaprevir Open-Label Study in Co-Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-06","conditions":"Hepatitis C, Chronic","enrollment":122},{"nctId":"NCT01434654","phase":"","title":"Efficacy of Neuro-HAART in Patients With HIV","status":"TERMINATED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2011-09","conditions":"HIV","enrollment":19},{"nctId":"NCT01448486","phase":"PHASE4","title":"A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV","status":"TERMINATED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2011-10","conditions":"Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)","enrollment":6},{"nctId":"NCT01369056","phase":"NA","title":"HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence","status":"COMPLETED","sponsor":"University of Tartu","startDate":"2010-07","conditions":"Acute HIV Infection, Acquired Immunodeficiency Syndrome, Medication Adherence","enrollment":150},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT02713750","phase":"","title":"RH and Adolescents","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2013-03","conditions":"Reproductive Health","enrollment":77},{"nctId":"NCT00833781","phase":"PHASE1, PHASE2","title":"A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-08","conditions":"HIV-1 Infection, HIV Infections","enrollment":15},{"nctId":"NCT01644370","phase":"NA","title":"Children With HIV and Asthma (CHIVAS)","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2011-09","conditions":"T Cell Response to Asthma in HIV-infected Patients Before and After Starting Treatment","enrollment":20},{"nctId":"NCT01367210","phase":"PHASE4","title":"Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)","status":"TERMINATED","sponsor":"Catholic University of the Sacred Heart","startDate":"2011-06","conditions":"HIV Infection","enrollment":165},{"nctId":"NCT01515813","phase":"PHASE2","title":"Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation","status":"WITHDRAWN","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2011-11","conditions":"HIV-1 Infection","enrollment":""},{"nctId":"NCT00408642","phase":"PHASE3","title":"An Enhanced Adherence Support Programme for Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2007-08","conditions":"HIV Infections","enrollment":297},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334},{"nctId":"NCT01338025","phase":"PHASE4","title":"Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy","status":"TERMINATED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2011-03","conditions":"HIV Disease","enrollment":33},{"nctId":"NCT02526940","phase":"","title":"Impact of Pre-ART Blood CD4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2015-05","conditions":"Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT01020045","phase":"","title":"Effect of HIV Infection and Highly Active Antiretroviral Treatment (HAART) on Bone Homeostasis","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-10","conditions":"HIV Infection, Osteopenia, Osteoporosis","enrollment":120},{"nctId":"NCT02167100","phase":"","title":"Patient Retention in HIV Medical Care in a Primary Care Practice in Australia","status":"COMPLETED","sponsor":"Holdsworth House Medical Practice","startDate":"2014-06","conditions":"HIV","enrollment":1537},{"nctId":"NCT02069834","phase":"PHASE2, PHASE3","title":"Dolutegravir + Rilpivirine Switch Study (DORISS)","status":"WITHDRAWN","sponsor":"Nantes University Hospital","startDate":"2014-05","conditions":"HIV Infection, HAART-treated, Virologically Controlled","enrollment":""},{"nctId":"NCT00487188","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-11","conditions":"HIV Infections","enrollment":47},{"nctId":"NCT02515240","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in HIV Infected Individuals","status":"COMPLETED","sponsor":"University of Toledo Health Science Campus","startDate":"2010-07","conditions":"Pneumococcal Infection","enrollment":124},{"nctId":"NCT00352053","phase":"PHASE3","title":"Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2006-06","conditions":"HIV Infections","enrollment":87},{"nctId":"NCT01088516","phase":"PHASE4","title":"Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa","status":"COMPLETED","sponsor":"University of Zambia","startDate":"2008-12","conditions":"HIV","enrollment":280},{"nctId":"NCT00001131","phase":"NA","title":"Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-05","conditions":"HIV Infections","enrollment":42},{"nctId":"NCT00050089","phase":"NA","title":"CSP #512 - Options in Management With Anti-Retrovirals","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2001-01","conditions":"AIDS, HIV Infections","enrollment":368},{"nctId":"NCT00709007","phase":"PHASE2, PHASE3","title":"Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2008-07","conditions":"HIV Infections, Heroin Dependence","enrollment":""},{"nctId":"NCT00737724","phase":"NA","title":"Simultaneous Versus Sequential Antiretroviral Therapy (ARV) Therapy and Mycobacterium Tuberculosis (MTB) Treatment","status":"TERMINATED","sponsor":"Instituto Nacional de Enfermedades Respiratorias","startDate":"2008-03","conditions":"HIV, AIDS, Tuberculosis","enrollment":63},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":7626,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"highly active antiretroviral therapy (HAART)","genericName":"highly active antiretroviral therapy (HAART)","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}